HALOHalozyme Therapeutics, Inc.
Is the price fair?
Neither cheap nor expensive: modest expectations priced in and cheap vs its sector, but at the top of its own P/E range.
Priced for a decline (~−3% a year). The price demands less than its three-year revenue growth of 29% a year, expectations look modest.
Expensive vs its own history: P/E 32.2 vs a 20.3 median over 24 quarters (+59% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What HALO's price assumes
Halozyme Therapeutics, Inc. trades at 32.2× earnings against 18.8× for the median Biotechnology name, more expensive than its own group.
Trailing P/E · Biotechnology median 18.8 · 1.71× the median: the market pays up for this one
- Price / sales
- 5.18
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 9.4%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- −2.7%
Growth the price implies · The price pays for −2.7% free cash flow growth a year for a decade; the business has delivered +41% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 60.0
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 17.8
- EV / salestoday's price, trailing year to Jun 30, 2026
- 6.37
- Healthcare median P/E509 names
- 26.2
- Biotechnology median P/E244 names
- 18.8
- Free cash flow, trailing twelve months
- $806M
- Market capitalisation
- $8.62B
- 3-year revenue growth
- +29%
- 3-year free cash flow growth
- +41%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $56.48 |
| Its own P/E history, median | $69.65 |
| Its own P/E history, upper quartile | $93.23 |
| 52-week range | $61.63 – $115.27 |
| Today | $110.41 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.